Getting molnupiravir to patients in a timely way is likely to be problematic
- PMID: 34728494
- DOI: 10.1136/bmj.n2648
Getting molnupiravir to patients in a timely way is likely to be problematic
Conflict of interest statement
Competing interests: PMBE is on the editorial board of Vaccines Today: an unpaid, voluntary, position. While he is also a member of the BMA’s Public Health Medicine Committee, this comment is made in a personal capacity. PMBE sometimes receives honoraria for acting as a consultant to various vaccine manufacturers, most recently to Seqirus.
Comment on
-
Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports.BMJ. 2021 Oct 4;375:n2422. doi: 10.1136/bmj.n2422. BMJ. 2021. PMID: 34607801 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical